News
Clinical Trials Arena on MSN22h
Anavex’s blarcasemine nets win in Phase IIb/III Alzheimer’s extension studyAnavex's blarcasemine met its primary endpoints, improving cognition and function over a four year period in early-stage Alzheimer’s patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback